Milestone Pharmaceuticals Q3 EPS $(0.35) Beats $(0.38) Estimate; Cash, Cash Equivalents, And Short-term Investments Of $75.7M Are Expected To Fund Operations Into Mid-2025
Portfolio Pulse from Benzinga Newsdesk
Milestone Pharmaceuticals (NASDAQ:MIST) reported a Q3 EPS loss of $(0.35), surpassing the consensus estimate of $(0.38) by 7.89%. The loss represents a slight increase from the $(0.34) per share loss in the same quarter last year. The company's cash reserves of $75.7M are expected to fund operations into mid-2025.
November 13, 2023 | 11:59 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Milestone Pharmaceuticals reported a smaller-than-expected Q3 loss and has sufficient cash to fund operations into mid-2025.
Beating EPS estimates typically has a positive impact on investor sentiment, which can lead to a short-term increase in stock price. The assurance of funding into mid-2025 also adds financial stability to the company, which investors may view favorably.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100